Profacgen Introduces Enhanced ChIP Assay Service with Integrated ChIP-seq and Functional Analysis

June 25, 2025 12:30 AM AEST | By EIN Presswire
 Profacgen Introduces Enhanced ChIP Assay Service with Integrated ChIP-seq and Functional Analysis
Image source: EIN Presswire
NEW YORK, NY, UNITED STATES, June 24, 2025 /EINPresswire.com/ -- Profacgen, a well-regarded provider of custom protein and genomic analysis solutions, has launched an expanded version of its Chromatin Immunoprecipitation (ChIP) Assay Service. This isn't just a technical revision—it’s a shift in how researchers can approach genome-wide studies of protein-DNA interactions. With high-precision ChIP-seq now built in, and new bioinformatics layers added to the pipeline, the service offers clearer data and more meaningful interpretation.

To study how genes are turned on or off, one often needs to start with where proteins bind on the genome. This is where DNA-Protein Interaction Analysis becomes critical. Transcription factors, histone modifications—these elements decide whether a gene stays silent or becomes active. When something goes wrong in these interactions, diseases often follow. While traditional ChIP has long been a key tool for mapping those sites, it doesn’t always offer the resolution or efficiency today’s researchers need.

That’s what this upgrade addresses. Profacgen has combined a thoroughly validated immunoprecipitation process with next-generation sequencing. The result? A more reliable way to see how chromatin is structured and how regulatory networks function.

“This isn’t just another sequencing service,” said Ellen, Chief Marketing Officer at Profacgen. “We’re giving scientists a more intuitive way to track how proteins interact with DNA in different tissues or under changing conditions. It’s not only about data—it’s about building a biological narrative.”
As Ellen explains, several improvements now come standard:

Genome-wide mapping of transcription factor and histone modification binding sites, powered by high-resolution ChIP-seq.

Integrated functional analysis using GO enrichment, KEGG pathway mapping, and motif discovery.

Seamless combination of high-quality library prep with Illumina NextSeq 500 sequencing, delivering both depth and consistency.

Visualized reports with peak annotation, pathway association, and sequence motif results—ready for interpretation.

The entire service rests on a streamlined workflow. From receiving cells to chromatin shearing, antibody-based enrichment, library construction, and sequencing, each step has been designed for efficiency. Once the data is in, Profacgen runs it through a multi-layered analysis framework. What comes out isn’t just a file—it’s a full picture of chromatin states and their biological significance.

Whether the study centers on cancer biology, immune regulation, or developmental processes, this platform helps researchers connect molecular interactions to larger biological questions. “We believe that real scientific value doesn’t just come from data collection,” Ellen added. “It comes from how that data is interpreted, visualized, and turned into insight.”

To learn more about Profacgen’s ChIP Assay Service and its applications in transcriptional and epigenetic research, please visit:
https://www.profacgen.com/chromatin-immunoprecipitation-chip-assay-service.htm

Ellen Burns
Profacgen
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.